Anaemia in chronic kidney disease

被引:0
|
作者
van Hougenhouck-Tulleken, W. [1 ]
机构
[1] Univ Pretoria, Pretoria, South Africa
关键词
anaemia in chronic kidney disease (AiCKD); haemoglobin; iron; erythropoietin; uraemic toxins; ANGIOTENSIN-RECEPTOR BLOCKERS; INHIBITORS;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Anaemia, occurring in over 50% of patients with stages 3 to 5 chronic kidney disease (CKD), often causes fatigue, shortness of breath, cardiac dysfunction and cognitive impairment. The major causes include disorders of iron metabolism (both iron deficiency and iron blockade) and erythropoietin deficiency. Treatment should be aggressive, and treated to specific targets. Nutritional deficiencies should be treated first, and only once replete, should erythropoiesis-stimulating agents (EPO-stimulating agents [ESAs]) be considered. Careful consideration must be given to the adverse effects of ESAs, and prescribed only after discussion with the patient. Patients with refractory anaemia, rapidly deteriorating glomerular filtration rate (GFR), and who have stage 3-5 CKD should be referred timeously to a nephrologist.
引用
收藏
页码:22 / 24
页数:3
相关论文
共 50 条
  • [31] UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease
    Sunil Bhandari
    Sebastian Spencer
    Ben Oliveira
    Ashraf Mikhail
    Owain Brooks
    Gareth Bryant
    Michelle Willicombe
    Richard Baines
    Louise Alldridge
    Sally Haslam-England
    BMC Nephrology, 26 (1)
  • [32] Gastrointestinal tract pathology in patients with asymptomatic anaemia and chronic kidney disease
    Powell, N.
    McNair, A.
    GUT, 2007, 56 : A83 - A83
  • [33] Non-erythropoietin-based anaemia management in chronic kidney disease
    Hörl, WH
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 : 35 - 38
  • [34] New treatment approaches in chronic kidney disease-associated anaemia
    Del Vecchio, Lucia
    Locatelli, Francesco
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (05) : 687 - 696
  • [35] CANAGLIFLOZIN IMPROVES ERYTHROPOIESIS IN DIABETES PATIENTS WITH ANAEMIA OF CHRONIC KIDNEY DISEASE
    Maruyama, Takashi
    Takashima, Hiroyuki
    Abe, Masanori
    NEPHROLOGY, 2020, 25 : 72 - 72
  • [36] Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease
    Natale, Patrizia
    Palmer, Suetonia C.
    Jaure, Allison
    Hodson, Elisabeth M.
    Ruospo, Marinella
    Cooper, Tess E.
    Hahn, Deirdre
    Saglimbene, Valeria M.
    Craig, Jonathan C.
    Strippoli, Giovanni F. M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (08):
  • [37] Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease
    Mikhail, Ashraf
    Brown, Christopher
    Williams, Jennifer Ann
    Mathrani, Vinod
    Shrivastava, Rajesh
    Evans, Jonathan
    Isaac, Hayleigh
    Bhandari, Sunil
    BMC NEPHROLOGY, 2017, 18
  • [38] Snap shot view on anaemia in chronic kidney disease of uncertain aetiology
    Fernando, Warnakulasuriya B. N. T.
    Hettiarachchi, Thilini W.
    Sudeshika, Thilini
    Badurdeen, Zeid
    Abeysundara, Hemalika
    Ranasinghe, Shirani
    Rathnayake, Manel P.
    Nanayakkara, Nishantha
    NEPHROLOGY, 2019, 24 (10) : 1033 - 1040
  • [39] Current and future chemical therapies for treating anaemia in chronic kidney disease
    Locatelli, Francesco
    Del Vecchio, Lucia
    Luise, Maria Carmen
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (08) : 781 - 788
  • [40] Renal Association Clinical Practice Guideline on Anaemia of Chronic Kidney Disease
    Mikhail, Ashraf
    Shrivastava, Rajesh
    Richardson, Donald
    NEPHRON CLINICAL PRACTICE, 2011, 118 : C101 - C124